Practical guide to hereditary breast and ovarian cancer : annual meeting of the Japanese Organization of Hereditary Breast and Ovarian Cancer 2021 / Daisuke Aoki, Seigo Nakamura, Yoshio Miki, editors.
Japanese Organization of Hereditary Breast and Ovarian Cancer. Annual Meeting (2021); Aoki, Daisuke.; Nakamura, Seigo.; Miki, Yoshio (Of Tōkyō Ika Shika Daigaku)
2023
RC280.B8
Available Online

Linked e-resources

Linked Resource Online Access
Concurrent users Unlimited
Authorized users Authorized users
Document Delivery Supplied Can lend chapters, not whole ebooks

Details

Title Practical guide to hereditary breast and ovarian cancer : annual meeting of the Japanese Organization of Hereditary Breast and Ovarian Cancer 2021 / Daisuke Aoki, Seigo Nakamura, Yoshio Miki, editors.
Corporate Author Japanese Organization of Hereditary Breast and Ovarian Cancer. Annual Meeting (2021)
ISBN 9789819952311 (electronic bk.)
981995231X (electronic bk.)
9819952301
9789819952304
DOI https://doi.org/10.1007/978-981-99-5231-1
Publication Details Singapore : Springer, 2023.
Language English
Description 1 online resource
Item Number 10.1007/978-981-99-5231-1 doi
Call Number RC280.B8
Dewey Decimal Classification 616.99/449
Summary This book shares cutting-edge evidence on Hereditary Breast and Ovarian Cancer (HBOC) treatment, delivering facts on breast cancer, gynecologic oncology, and basic research to contribute to clinicians' practices. Each chapter presents the latest clinical techniques, basic experimental results, and the best-chosen research findings. The book is based on the works presented at the Japanese Organization of Hereditary Brest and Ovarian Cancer (JOHBOC) and a special chapter delivers a study based on the extensive data from the Japanese HBOC patients registered in the society's database, presenting novel evidence for further advancement in the field. The practice for HBOC has been rapidly increasing due to the clinical development of poly(ADP-ribose) polymerase inhibitors and the spread of companion diagnostics. In addition, the insurance coverage of a part of HBOC treatment raised social awareness in Japan, and the book illustrates not only clinical efforts but also issues related to the social system and the efforts of the association of related organizations. Hereditary Breast and Ovarian Cancer Annual meeting of JOHBOC will be of interest to breast surgeons, obstetricians and gynecologists, pancreatic cancer surgeons, and urologists engaged in HBOC treatment through the implementation of companion diagnostics for PARP inhibitors administration. Also, physicians occupied in genetic medicine who perform genetic testing and medical staff practicing HBOC will find this book insightful. It is also for HBOC patients and their families, medical administrators in the social system of HBOC practice. Editors and authors hope to contribute to the equalization and widespread of HBOC practice and serve as a foundation for future advances in the disease's treatment and medical practice.
Bibliography, etc. Note References -- Mutual Feedback Between Gynecological HBOC Practice and Cancer Genomic Medicine -- 1 Introduction -- 2 Characteristics of HBOC Ovarian Cancer -- 3 PARP Inhibitor -- 4 Biomarkers of PARP Inhibitors -- 4.1 Platinum-Sensitivity Status -- 4.2 BRCA1/2 Testing -- 4.3 SNP-Based Genomic Scar Assays -- 5 New Candidates for Evaluating HRD Status -- 5.1 Homologous Recombination Repair (HRR)-Related Gene Mutations -- 5.2 Mutation Signatures -- 6 Clinical Use of PARP Inhibitors for Ovarian Cancer in Japan -- 7 Conclusion -- References -- Part III: Basic Science
Access Note Access limited to authorized users.
Added Author Aoki, Daisuke.
Nakamura, Seigo.
Miki, Yoshio (Of Tōkyō Ika Shika Daigaku)
Available in Other Form Print version: 9789819952304
Linked Resources Online Access
Record Appears in Online Resources > Ebooks
All Resources
Intro
Contents
Part I: Breast
Establishment of a Medical System with HBOC in Mind
1 Introduction
1.1 History of BRCA1/2 Clinical Practice in Japan
1.2 BRCA1/2 Genetic Test
1.3 Risk Reduction Surgery
1.4 Surveillance
1.5 PARP Inhibitor
1.6 Chemoprevention
1.7 Beyond HBOC
1.8 Genetic Test for Family
2 Conclusion
References
Guidelines for Diagnosis and Treatment of HBOC: Methods and Products
1 Purpose of the Guidelines
2 Significance of Guideline Creation
3 Method of Preparation of These Guidelines
3.1 Preparation Members

3.2 Establishment of Clinical Queries
3.3 Systematic Review and Evidence Synthesis
3.4 Recommendation-Making
4 Type of Recommendation
5 External Evaluation
6 Summary
HBOC from a Plastic Surgeon's Perspective
1 Breast Reconstruction in Japan
2 RRM and Breast Reconstruction for HBOC in the Era of Self-Funded Treatment
3 BIA-ALCL and the "Allergan Crisis" in Japan
4 Properly Fearing BIA-ALCL
5 Breast Reconstruction After RRM After Insurance Coverage of RRM
6 Fat Grafting
7 Lifestyle and Life Stage
References
Part II: Gynecology

Serous Tubal Intraepithelial Carcinoma (STIC) and Precancerous Lesions in Risk-Reducing Salpingo-oophorectomy (RRSO) Specimens
1 Introduction
2 HBOC and Ovarian Cancer
3 Significance of RRSO and Pathological Examination
4 Occult Cancer in RRSO Specimens
5 Precancerous Lesions in RRSO Specimens
5.1 STIC
5.1.1 STIC in RRSO Specimens
5.1.2 STIC Coexisting with HGSC
5.1.3 STIC in Benign Gynecological Specimens
5.2 STIL, p53 Signature
5.2.1 Frequencies of STIL and p53 Signature (Table 1)
5.2.2 Significance of p53 Signature and STIL
6 Future Prospective

Heterogeneities in Hereditary Cancer Genes as Revealed by a Large-Scale Genome Analysis
1 Background
1.1 Limited Information on Personalized Medicine for BRCA1 and BRCA2
1.2 Importance of Large-Scale Data
2 Risk and Frequency of Pathogenic Variants in 27 Hereditary Cancer Genes
2.1 BioBank Japan
2.2 Sequencing
2.3 Clinical Interpretation of Genetic Variants
2.4 Unified Analysis of >66,000 Individuals with Five Cancer Types
2.5 Risk and Frequency of Pathogenic Variants
2.6 Variants of Uncertain Significance
3 Heterogeneity
3.1 Between Genes

Browse Subjects

Show more subjects...

Statistics

from
to
Export